Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LFGuard Vaccine
- Development stage
- Preclinical
- Lead developer
- PAI Life Sciences
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
LFGuard is a prophylactic vaccine candidate being developed by PAI Life Sciences, in collaboration with the University of Illinois, for the prevention of lymphatic filariasis (LF). The vaccine consists of a recombinant, tag-free tetravalent fusion protein antigen known as rBmHAXT, which comprises four antigens (BmHsp12.6, BmALT-2, BmTSPLEL, and BmTPX-2) from the parasitic nematode *Brugia malayi*. LFGuard is formulated with a Toll-like receptor 4 (TLR4) agonist adjuvant, such as GLA-on-Alum (AL019) or Al-T4, to stimulate a balanced Th1/Th2 immune response and generate protective antibodies and memory T cells. The vaccine is currently in preclinical development, with cGMP manufacturing and IND-enabling studies underway to support progression to Phase 1 clinical trials.
- Brand names
- LFGuard
- Other names
- lymphatic filariasis vaccinerBm-HAXT vaccinerBmHAXT vaccine
02
Targets
MYD88 (Myeloid differentiation primary response protein MyD88)NF-κBTRIF (TIR-domain-containing adapter-inducing interferon-beta)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LFGuard Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LFGuard Vaccine.